Skip to content
vigabatrin.org

Vigabatrin brand names and generics

On this page

Short answer: in the US, vigabatrin is sold as Sabril (500 mg tablets and 500 mg powder packets), as Vigafyde (a ready-to-use liquid, 100 mg per mL), and as generics such as Vigadrone (powder packets and tablets) and Vigpoder.1,2,3 Every product contains the same medicine, carries the same boxed warning about permanent vision loss, and is dispensed only through the Vigabatrin REMS.4,5

What differs between them is the form, how each dose is prepared, and who it is labeled for.

US vigabatrin products

ProductFormStrengthLabeled forFDA application
Sabril tabletsFilm-coated, scored tablet500 mgRefractory complex partial seizures, age 2 and upNDA 0204271
Sabril for oral solutionPowder packets, mixed with water500 mg per packetInfantile spasms, 1 month to 2 years; refractory complex partial seizures, age 2 and upNDA 0220061
VigafydeReady-to-use oral solution100 mg per mL, 150 mL bottleInfantile spasms only, 1 month to 2 yearsNDA 2176842
Vigadrone for oral solutionPowder packets, mixed with water500 mg per packetInfantile spasms, 1 month to 2 years; refractory complex partial seizures, age 2 and upANDA 2101963,6
Vigadrone tabletsFilm-coated, scored tablet500 mgInfantile spasms, 1 month to 2 years; refractory complex partial seizures, age 2 and upANDA 2147497,8
VigpoderPowder for oral solution500 mg per packetSee its labelANDA 2149613
Other genericsPowder packets or tablets500 mgSee each labelSeveral ANDAs3

Sabril

Sabril is the original vigabatrin brand. Its tablets and its powder for oral solution were both approved on 21 August 2009. The application holder is Lundbeck.1

The powder is labeled for infantile spasms from 1 month to 2 years and, as an add-on treatment, for refractory complex partial seizures from age 2.9

Vigafyde

Vigafyde is a ready-to-use oral solution, 100 mg per mL, approved on 17 June 2024. The application holder is Pyros.2 The current Vigafyde label lists Upsher-Smith as the distributor, while Pyros holds the NDA.2,4 It comes in a 150 mL bottle, needs no mixing, and is kept for up to 90 days after opening.4

Vigafyde is labeled only for infantile spasms in babies 1 month to 2 years old. It is not approved for refractory complex partial seizures or for adults.4 Its approval was based on comparing its composition with vigabatrin powder solution, not on new efficacy trials.4

In the FDA's records, Vigafyde was the only vigabatrin product listed as a ready-to-use solution. Every generic was a powder or a tablet.3

Because it is twice as concentrated as mixed powder, the same number of mL gives twice the dose. The label warns prescribers, pharmacists and caregivers to check the volume when switching.4

Vigadrone

Vigadrone is the Upsher-Smith brand of generic vigabatrin, sold in two forms. The powder for oral solution was approved on 21 June 2018 under ANDA 210196, and DailyMed now lists Upsher-Smith as its labeler.3 The 500 mg tablets were approved on 29 June 2023 under ANDA 214749.7 They are film-coated and scored, in bottles of 100.8 Both Vigadrone labels cover infantile spasms from 1 month to 2 years and, as an add-on, refractory complex partial seizures from age 2.6,8

The powder comes in 500 mg packets in cartons of 50, and it is mixed exactly like Sabril powder: 10 mL of water per packet, 50 mg per mL, each dose made fresh and the rest discarded.6

A 2025 lab study by authors from Upsher-Smith and Aucta found Vigadrone powder stayed stable for 48 hours in the fridge when mixed in water, juice, milk or formula. The label still says water only.10

Vigpoder and other generics

Vigpoder is a generic vigabatrin powder for oral solution, 500 mg per packet, approved under ANDA 214961; the application holder is Pyros. Teva, Amneal, Dr. Reddy's, Zydus and others hold approvals for generic vigabatrin powder packets or 500 mg tablets.3

What generic means here

A generic is approved through an abbreviated new drug application (ANDA). The generic vigabatrin products in FDA records are 500 mg powder packets and 500 mg tablets, the same strengths as Sabril.1,3 Vigadrone powder is mixed the same way as Sabril powder.6,9 Which product you receive may depend on your insurance and pharmacy.

Reading the FDA labels

The full prescribing information is the most reliable source for any product. Current versions are on DailyMed:

  • Vigafyde oral solution4
  • Sabril for oral solution9
  • Sabril tablets5
  • Vigadrone for oral solution6
  • Vigadrone tablets8

We also keep copies of two FDA labels as PDFs: the Vigafyde label as first approved in 2024, and the Sabril label covering tablets and powder. Labels are revised over time, so check DailyMed for the latest wording.

Common questions

What is the brand name of vigabatrin?

In the US, the original brand is Sabril, with 500 mg tablets and 500 mg powder packets approved by the FDA in 2009. Vigafyde is a newer brand, approved in 2024, and is a ready-to-use liquid. Vigadrone and Vigpoder are generic versions, and several other companies make generics.

Is Vigadrone the same as Sabril?

Vigadrone is a generic version of Sabril. It comes as a powder for oral solution, approved in 2018, and as 500 mg tablets, approved in 2023. The powder comes in 500 mg packets in cartons of 50 and is mixed the same way as Sabril powder: 10 mL of water per packet, made fresh for each dose.

Is there a generic of Vigafyde?

In FDA records, Vigafyde is the only ready-to-use vigabatrin solution. The generic vigabatrin products listed there are powder packets or tablets.

Do all vigabatrin brands carry the vision-loss warning?

Yes. Every vigabatrin product contains the same medicine, carries the boxed warning about permanent vision loss and is available only through the Vigabatrin REMS program.

References

  1. 1.Drugs@FDA: NDA 020427 SABRIL tablet 500 mg and NDA 022006 SABRIL for oral solution 500 mg/packet, Lundbeck. Both approved 2009-08-21. Source
  2. 2.Drugs@FDA (openFDA API): NDA 217684, VIGAFYDE (vigabatrin) oral solution 100 mg/mL, sponsor Pyros Pharms; original approval 2024-06-17. Source
  3. 3.Drugs@FDA (openFDA): numerous ANDAs for vigabatrin for oral solution 500 mg/packet and tablets 500 mg. Examples: VIGADRONE ANDA 210196 (approved 2018-06-21; DailyMed labeler now Upsher-Smith); VIGPODER ANDA 214961 (Pyros; openFDA product: vigabatrin 500MG/PACKET, dosage form "FOR SOLUTION", route oral, TE code AA, i.e. a powder for oral solution; original approval 2022-06-24; no current DailyMed SPL found under the name Vigpoder); Teva, Amneal, Dr. Reddy's, Zydus and others. VIGAFYDE was the only vigabatrin "SOLUTION" (ready-to-use) dosage form in the results. Source
  4. 4.VIGAFYDE (vigabatrin) oral solution prescribing information, revised 11/2025. Source
  5. 5.SABRIL (vigabatrin) tablets prescribing information, revised 10/2021. Source
  6. 6.VIGADRONE (vigabatrin) for oral solution, revised 12/2025, Upsher-Smith. Source
  7. 7.Drugs@FDA (openFDA API): ANDA 214749, vigabatrin tablet 500 mg, sponsor Upsher-Smith Labs; original approval 2023-06-29; marketing status Prescription; TE code AB. openFDA brand name for this application: VIGADRONE (Upsher-Smith Laboratories, LLC; NDC 0245-6001). Source
  8. 8.VIGADRONE (vigabatrin) tablets prescribing information, Upsher-Smith Laboratories, LLC (Medication Guide revised 3/2023). ANDA 214749. Source
  9. 9.SABRIL (vigabatrin) for oral solution prescribing information, revised 10/2021. Source
  10. 10.Zachman M, Gong L, An L, Halvorsen MB. Dissolution and stability of vigabatrin powder in water, fruit juice, milk, and infant formula. Epilepsy Behav Rep. 2025;31:100816. PMID 40838171 · DOI 10.1016/j.ebr.2025.100816 PubMedDOI

All sources used on this site, with summaries